Prospective Process Validation of Vitamin-E 200 (Alpha Tocopherol Acetate BP 200 Mg) Capsule

Authors: Shome M*, Sarker BK, Rahman FS, Chowdhury K, Kundu SK

Journal: Nanomedicine & Nanotechnology Open Access. Article type: Review Article. Published: 2024-12-11. DOI: https://doi.org/10.23880/nnoa-16000330

Abstract

Process validation is a documented evidence which provides a high degree of assurance that a specific process will consistently produce a result meeting its predetermined specifications and quality attributes. Validation is documented act of proving that any procedure, process or system that actually leads to a expected result. The purpose of this investigation is to study prospective process validation of Vitamin-E 200 (Alpha Tocopherol Acetate BP 200 mg) capsule. Quality cannot be adequately assured by in-process inspections and testing but it should be built into the manufacturing process. This process should be controlled in order that the finished product meets all quality specifications. Therefore, building of quality requires careful attention to a number of factors, such as the selection of materials, product and process design, control variables in-process inspection. The critical process parameters were identified with the help of process capability and evaluated by challenging its lower and upper release specifications. Three initial process validation batches of same batch size, method, equipment, & validation criteria were taken. The critical parameters involved in dispensing, mixing (preparation of bulk solution), band solution preparation, encapsulation and band sealing stages were identified and evaluated as per validation plan. The outcome indicates that this process validation data provides high degree of assurance that manufacturing process produces product meeting its predetermined specifications and quality attributes which is in compliance with the GMP.

Keywords: Prospective Process Validation, Control Variables, In-Process Control

Abbreviations

CGMP: Current Good Manufacturing Practices; BMR: Batch Manufacturing Record; BPR: Batch Packaging Record.

Introduction

In the mid-1970s, Ted Bayer and Bud Loftus, two officials from the FDA, introduced the concept of validation.

Validation aims to guarantee that quality is integrated into the system at every stage, rather than solely being tested at the end. Therefore, validation activities frequently encompass training on production materials and operating procedures, educating the individuals involved, and overseeing the system during production. This has become a valuable component of current good manufacturing practices (cGMP).

**According to US FDA**: Establishing documented evidence for process validation provides a high level of confidence that a particular process will consistently meet its earlier set-up specifications and quality standards.

**According to WHO** [1]: Validation studies are a very important aspect of GMP and must adhere to a predetermined protocol. The results and conclusions should be documented, compiled, and stored in writing. Processes and procedures should be developed based on the WHO’s validation study and should undergo regular revalidation to ensure they are still capable of achieving the desired results. Process validation is the gathering and analysis of data from the process design phase through commercial production, providing scientific proof that a process can consistently produce high-quality products. It encompasses a series of activities throughout the product and process lifecycle, including process design, process qualification, and ongoing process verification.

Types of Process Validation

**Prospective Process Validation:** In prospective process Validation, prior to the process being used commercially, an experimental plan known as the validation protocol is carried out in prospective process validation. Before launching the product commercially into the market, a pre- planned protocol, it is the verified, documented proof that a system performs as intended [2]. **Retrospective Validation:** For well-known items with stable manufacturing processes, the retrospective validation option is selected. Establishing recorded proof that a process performs as intended through the examination and analysis of past data is known as retrospective validation. **Concurrent Validation:** Concurrent validation is considered for the running production products because somehow their validation was not performed before launching the products i.e. at the Prospective Process Validation stage. Based on data produced during the actual execution of the process, concurrent validation is used to create documented proof that a facility and its procedures perform as intended. To demonstrate that the manufacturing process is under control, this method entails evaluating the finished product of ongoing production and monitoring crucial processing steps. **Revalidation:** Revalidation is conducting an investigative evaluation of the performance data that has already been collected and involves repeating the first validation effort or any portion of it. Maintaining the validated condition of the plant, machinery, manufacturing procedures, and computer systems require this strategy. The followings are some potential justifications for initiating the revalidation process: • The movement of a product from one plant to another. • Changes to the product, the factory, the producing procedure, the cleansing procedure, or different adjustments that would have an effect on product quality. • Significant (generally order of magnitude) boom or lower in batch size. • Sequential batches that fail to satisfy product specifications and validated standard procedure. • The scope of revalidation tactics relies upon at the volume of the adjustments and the impact upon the product quality [3].

Process Validation Protocol

Prior to beginning any process validation works, the following items must be finished in order to complete the qualification process. The process validation will begin once the qualification work is finished [4].

**Design Qualification:** The recorded review of technical specifications and planning papers to ensure that the design complies with manufacturing process, GMP, and regulatory standards is known as DQ. **Installation Qualification:** The documented confirmation that the building, HVAC system, auxiliary utilities, and equipment were constructed and installed in accordance with their authorized design specifications is known as IQ **Operational Qualification:** OQ serves as the documentation proof that the equipment performs as intended across all expected operating ranges and complies with design specifications within its typical operating range. **Performance Qualification:** PQ is the documented confirmation that the process, or the system’s entire process, operates as planned across all expected operating ranges. And for the confirmation of the process, or the systems, three consecutive successful process validation batches have to be produced, and subsequently all the crucial process parameters will be checked with their predetermined specifications. Establishing documented proof that a particular process (like the production of pharmaceutical dosage forms) will reliably yield a product that satisfies its predefined specifications and quality attributes is known as process validation. A documented plan outlining the steps are involved in conducting Process Validation, including test parameters, product attributes, production tools, and design points regarding acceptable test results. In addition to being signed, dated, and numbered (document, protocol reference, and revision numbers), the validation protocol should include the following details at the very least [5]:

Principle

Process validation ensures that the manufacturing process controls are flexible enough to achieve desired qualities in the drug product while avoiding undesirable ones. This idea is crucial because it supports the definition of validation, which is a methodical process for identifying, quantifying, assessing, recording, and reassessing a number of crucial manufacturing process steps that need to be controlled in order to guarantee a repeatable end product. Machines and equipment used in the production of process validation batches must have their qualifications (IQ, OQ) fulfilled. This product’s raw materials must be purchased from authorized suppliers. Vitamin-E 200 (Alpha Tocopherol Acetate BP 200 mg) capsule analysis will be conducted using test methods for final product testing that have been satisfactorily validated by the R&D department. Every employee who makes Vitamin-E 200 (Alpha Tocopherol Acetate BP 200 mg) capsules has received specialized training on how to follow SOP, BMR,

General Information

and BPR during the manufacturing process. The factors that affect each processing step’s outcome are first determined, and they are then further separated into those that changed during processing and could affect the final product’s quality and outcome. A Batch Manufacturing Record (BMR) and Batch Packaging Record (BPR) must be finalized for use in regular manufacturing after the validation process is finished. Change control management must be applied, if any deviation is found in the Batch Manufacturing Record (BMR) and Batch Packaging Record (BPR) after finalization the BMR & BPR [6].

Objective

The duties and tasks to clarify the essential details of the production process of vitamin-E 200 (Alpha Tocopherol Acetate BP 200 mg) capsules are described in this process validation protocol. This protocol’s goal is to specify the tests, steps, and acceptance standards required to confirm that, when process parameters are set within acceptable bounds, the manufacturing process used to produce vitamin-E 200 capsules (Alpha Tocopheryl Acetate BP 200 mg per capsule) will produce batches of consistent quality [7].

Scope

This guidance document covers everything from packaging to the manufacturing process.

Qualification and Training of Personnel

Employees working on the validation project must be suitably qualified, trained in the fundamentals of validation, and fully briefed on the production of Vitamin-E 200 Capsules (Alpha Tocopheryl Acetate BP 200 mg per capsule) as well as the specific methodology to be used for the process’ performance qualification [8].

Formulation

The product formulation is as below:

Process Flow Diagram

Details of the Manufacturing Process

The manufacturing process of vitamin-E 200 capsule (Alpha Tocopheryl Acetate BP 200 mg per Capsule) is encapsulation type. And the Blister packing is Alu-PVC type. The process has been completed as at the following mentioned sequences [9]:

The process has been completed as per BMR (Document No.: BMR-CAP-001 and BPR (Document No.: BPR-CPP-001 and Document No.: BPR-CSP-001) [10].

[INLINE_TABLE:4:0]

Identification of Critical Process Parameters During Manufacturing

The critical process parameters as per manufacturing steps are described one after another as the following [11]:

[INLINE_TABLE:6:0]

List of Equipment and their Qualification Status

The list of equipment and their qualification status are stated in the following [12]:

Calibration and Qualification Status of Lab Equipment

The calibration and qualification status of the following equipment used in the Performance Qualification of process VITAMIN-E 200 capsule (Alpha Tocopheryl Acetate BP 200 mg per Capsule) shall be checked and listed in the following [13]:

Analytical Schedule

Sampling Details

**Sampling Points:** Intermediate bulk Container (SS Vessel). **Sample size:** For checking uniformity (1 gm ~ 2 gm each sample).

Testing Frequency

Method of Analysis

Analysis has been conducted as per validated & approved procedures

Acceptance Criteria and Results of Analysis

Graphical Presentation of Major Results

Specific Gravity

Active Distribution - Top

[INLINE_FIGURE:10:1]

Active Distribution – Middle

[INLINE_FIGURE:10:2]

Active Distribution – Bottom

Filling Weight

[INLINE_FIGURE:11:1]

Mass Variation

[INLINE_FIGURE:11:2]

Assay

Conclusion

Three consecutive batches (Batch numbers XX, YY, and ZZ) of VITAMIN-E 200 Capsules (Alpha Tocopheryl Acetate BP 200 mg per Capsule) underwent process validation, and all parameters were found to be within the acceptable range. The manufacturing process will reliably produce this product that satisfies its predetermined specifications and quality attributes, according to the results and graph of the validation data for these three batches mentioned above. Consequently, it can be said that the process used to manufacture this product is deemed to be validated and suitable for regular use in the production process.

Acknowledgement

The author of this paper is very much grateful to “The ACI Pharmaceuticals Ltd.; The ACME Laboratories Ltd.; Orion Pharmaceuticals Ltd and The Rangs Pharmaceuticals Ltd”, Dhaka, Bangladesh for providing all necessary facilities to carry out the entire works.

References

1. Good Manufacturing Practices: Guidelines on Validation (2019) WHO Technical Report, Series No: 1019.

2. USFDA Guideline for General Principle of Process Validation (2011) USA.

3. Nandhakumar L, Dharmamoorthy G, Rameshkumar S, Chandrasekaran S (2011) An Overview of Pharmaceutical Validation: Quality Assurance View Point. International Journal of Research in Pharmacy and Chemistry 1(4): 1003-1014.

4. Guideline on process validation for finished products (2016) EMA

5. Kavita, Kumar K, Morris SS, Tamta A, Kumar P, et al. (2013) Process Validation of Solid Dosage Form: A Review. An International Journal of Pharmaceutical Sciences 4(4): 387-401.

6. Frederick J, Carleton, Agalloco J (2007) Validation of Pharmaceutical Processes. In: 3rd (Edn.), Informa healthcare, New York, USA.

7. Q7a Good Manufacturing Practice Guideline for Manufacturing of Active Pharmaceutical Ingredients (2001) ICH Guideline.

8. WHO Guideline for Pharmaceutical Process Validation (1997) WHO.

9. Nash RA, Wachter H (2003) Pharmaceutical Process Vidation. In: 3rd (Edn.), Revised and Expnded, Marcel Dekker Inc, New York, USA.

10. US Food and Drug Administration Guideline on General Principles of Process Validation USFDA (1987) USA.

11. Levin M (2002) Pharmaceutical Process Scale-up. In: 1st (Edn.), Marcel Dekker Inc, New York, USA, pp: 313.

12. Lingnau J (1989) Optimization and Validation of Manufacturing Process. Drug Dev Ind Pharm 15(6-7): 1029-1046.

13. Raghunandanan R (2009) Validation Aspect of Solid Dosage Forms. Pharma Times 41(4): 15-18.

14. Nash RA (2002) Validation of pharmaceutical processes. In: Swarbrick J (Eds.), Encyclopedia of Pharmaceutical Technology. 2nd (Edn.), Marcel Dekker, New York, USA, pp: 2917-2931.

15. Heilman WP (1978) New drugs: Discovery and development (Drugs and the Pharmaceutical Sciences Series) Journal of Pharmaceutical Sciences 67(12): 1778.

16. Thakre S, Erande KB, Bhople A, Thakre A, Patil S (2013) Optimization and Validation of Process for Formulation and Coating of Ranitidine Hydrochloride tablets. Open Access Scientific Reports 2(2): 658.

17. Hojo T (2004) Quality Management System-Process Validation Guidance In: 2nd (Edn.), Global Harmonization Task Force, USA.

18. Bozzone S (2001) Process Validation of Solid Oral Dosage Forms, Part I General Principles, Ireland.

19. Neal C (2003) Prerequisites for Successful Validation. J Validation Tech 9: 240-244.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

General Information

Manufacturing Process Sequences

Checklist for manufacturing process observation

Analytical Schedule

Sampling Details

Testing Frequency

Acceptance Criteria and Results of Analysis

References

  1. Good Manufacturing Practices: Guidelines on Validation (2019) WHO Technical Report, Series No: 1019.
  2. USFDA Guideline for General Principle of Process Validation (2011) USA.
  3. Nandhakumar L, Dharmamoorthy G, Rameshkumar S, Chandrasekaran S (2011) An Overview of Pharmaceutical Validation: Quality Assurance View Point. International Journal of Research in Pharmacy and Chemistry 1(4): 1003-1014.
  4. Guideline on process validation for finished products (2016) EMA
  5. Kavita, Kumar K, Morris SS, Tamta A, Kumar P, et al. (2013) Process Validation of Solid Dosage Form: A Review. An International Journal of Pharmaceutical Sciences 4(4): 387-401.
  6. Frederick J, Carleton, Agalloco J (2007) Validation of Pharmaceutical Processes. In: 3rd (Edn.), Informa healthcare, New York, USA.
  7. Q7a Good Manufacturing Practice Guideline for Manufacturing of Active Pharmaceutical Ingredients (2001) ICH Guideline.
  8. WHO Guideline for Pharmaceutical Process Validation (1997) WHO.
  9. Nash RA, Wachter H (2003) Pharmaceutical Process Vidation. In: 3rd (Edn.), Revised and Expnded, Marcel Dekker Inc, New York, USA.
  10. US Food and Drug Administration Guideline on General Principles of Process Validation USFDA (1987) USA.
  11. Levin M (2002) Pharmaceutical Process Scale-up. In: 1st (Edn.), Marcel Dekker Inc, New York, USA, pp: 313.
  12. Lingnau J (1989) Optimization and Validation of Manufacturing Process. Drug Dev Ind Pharm 15(6-7): 1029-1046.
  13. Raghunandanan R (2009) Validation Aspect of Solid Dosage Forms. Pharma Times 41(4): 15-18.
  14. Nash RA (2002) Validation of pharmaceutical processes. In: Swarbrick J (Eds.), Encyclopedia of Pharmaceutical Technology. 2nd (Edn.), Marcel Dekker, New York, USA, pp: 2917-2931.
  15. Heilman WP (1978) New drugs: Discovery and development (Drugs and the Pharmaceutical Sciences Series) Journal of Pharmaceutical Sciences 67(12): 1778.
  16. Thakre S, Erande KB, Bhople A, Thakre A, Patil S (2013) Optimization and Validation of Process for Formulation and Coating of Ranitidine Hydrochloride tablets. Open Access Scientific Reports 2(2): 658.
  17. Hojo T (2004) Quality Management System-Process Validation Guidance In: 2nd (Edn.), Global Harmonization Task Force, USA.
  18. Bozzone S (2001) Process Validation of Solid Oral Dosage Forms, Part I General Principles, Ireland.
  19. Neal C (2003) Prerequisites for Successful Validation. J Validation Tech 9: 240-244.

PDF of this article

Related articles